Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans by Young Joo Jeon et al.
Jeon et al. BMC Cancer 2014, 14:881
http://www.biomedcentral.com/1471-2407/14/881RESEARCH ARTICLE Open AccessInterplay between 3′-UTR polymorphisms in the
vascular endothelial growth factor (VEGF) gene
and metabolic syndrome in determining the risk
of colorectal cancer in Koreans
Young Joo Jeon1,2†, Jong Woo Kim3†, Hye Mi Park1, Hyo Geun Jang1,2, Jung O Kim1,2, Jisu Oh4, So Young Chong4,
Sung Won Kwon3, Eo Jin Kim5, Doyeun Oh1,4* and Nam Keun Kim1,2*Abstract
Background: Polymorphisms in angiogenesis-related genes and metabolic syndrome (MetS) risk factors play
important roles in cancer development. Moreover, recent studies have reported associations between a number of
3′-UTR polymorphisms and a variety of cancers. The aim of this study was to investigate the associations of three
VEGF 3′-UTR polymorphisms (1451C > T [rs3025040], 1612G > A [rs10434], and 1725G > A [rs3025053]) and MetS with
colorectal cancer (CRC) susceptibility in Koreans.
Methods: A total of 850 participants (450 CRC patients and 400 controls) were enrolled in the study. The genotyping
of VEGF polymorphisms was performed by TaqMan allelic discrimination assays. Cancer risks of genetic variations and
gene-environment interactions were assessed by adjusted odds ratios (AORs) and 95% confidence intervals (CIs) of
multivariate logistic regression analyses.
Results: VEGF 1451C > T was significantly associated with rectal cancer risk (Dominant model; AOR =1.58; 95% CI =
1.09 - 2.28; p = 0.015) whereas VEGF 1725G > A correlated with MetS risk (Dominant model; AOR =1.61; 95% CI =1.06 -
2.46; p = 0.026). Of the gene-environment combined effects, the interaction of VEGF 1451C > T and MetS contributed to
increased rectal cancer risk (AOR = 3.15; 95% CI = 1.74 - 5.70; p < .001) whereas the combination of VEGF 1725G > A and
MetS was involved with elevated colon cancer risk (AOR = 2.68; 95% CI = 1.30 - 1.55; p =0.008).
Conclusions: Our results implicate that VEGF 1451C > T and 1725G > A may predispose to CRC susceptibility and the
genetic contributions may be varied with the presence of MetS.
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Colorectal cancer (CRC) is the third most common type
of cancer and the second leading cause of cancer-related
mortality in Western countries [1]. The prognosis of pa-
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unless otherwise stated.diagnosis. However, over 57% of patients have regional or
distant spread of tumor cells at the time of diagnosis [2].
The pathogenesis of CRC usually follows a stepwise pro-
gression from benign polyp to invasive adenocarcinoma. In
colorectal carcinogenesis, the unique molecular and genetic
changes that occur within cells result in a specific CRC
phenotype. This phenotype is associated with variable
tumor behaviors that are relevant to the prognosis and the
response to specific therapies. As a result, the term “CRC”
no longer refers to a single disease, but rather a heteroge-
neous group of diseases caused by differential genetic/epi-
genetic backgrounds. In this respect, many ongoing studies
are aimed at assessing biomarkers as potential predictors ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lead to the individualized management of the disease.
Tumor angiogenesis is important to tumor growth, as
evidenced by results showing that tumor growth is
dependent on angiogenesis. Furthermore, tumors are able
to produce diffusible angiogenic molecules [3], including
vascular endothelial growth factor (VEGF). VEGF is a key
regulator of angiogenesis with several functions that serve
to enhance tumor progression. These functions include
enhancing vascular permeability, inducing endothelial cell
migration and division, inducing serine protease activity,
inhibiting either the apoptosis of endothelial cells or mat-
uration of dendritic cells, and inducing angiogenesis [4,5].
The human VEGF gene is located on chromosome 6 and
organized into eight exons and seven introns, which
encode several different isoforms due to alternative splicing.
There are five well-studied VEGF polymorphisms that have
been linked to CRC: −2578C >A, −1498T >C, −1154G >
A, −634G >C, and 936C >T. However, their genetic associ-
ations with CRC have been inconsistent [6]. Recent papers
have shown some clinical impacts of polymorphisms in the
3′-UTR of certain genes, which may potentially bind to
specific miRNAs in various cancers [7-10]. However, vari-
ants in the VEGF 3′-UTR have not been studied.
The metabolic syndrome (MetS) is a portfolio of meta-
bolic disorders, including abdominal obesity, increased
blood pressure (BP), abnormal glucose metabolism, and
dyslipidemia [11]. Previous reports show that components
of MetS are associated with CRC susceptibility [12,13]. A
previous study found a 35% increased CRC risk associated
with high BP [14] and there was a similar finding in another
prospective epidemiologic study [15]. Adult-onset diabetes
mellitus (DM) has generally been associated with a higher
risk of CRC [16-20] and elevated blood glucose levels corre-
lated with a significantly elevated CRC risk (Relative risk
[RR] = 1.80) [21]. However, gene-environment combined
effects of MetS for CRC susceptibility have been infre-
quently found in previous published database.
In the VEGF gene, there are four known 3′-UTR poly-
morphisms (936C >T [rs3025039], 1451C >T [rs3025040],
1612G >A [rs10434], 1725G >A [rs3025053]). The VEGF
1451TT genotype presented a significant log-rank p value
in non-small-cell lung cancer survival [22]. The VEGF
1612A allele was associated with increased gastric cancer
risk [23]. The 936C >T polymorphism and its link to CRC
susceptibility have been published by our laboratory and
others [6,24]. The other three single nucleotide polymor-
phisms (SNPs) in the VEGF 3′-UTR, 1451C >T, 1612G >
A, and 1725G >A, are poorly understood in the context
of their genetic contributions to CRC susceptibility. The
purpose of this study was to investigate whether these poly-
morphisms of VEGF 3′-UTR correlate with CRC suscepti-
bility and the genetic contributions are modified by the
presence of MetS.Methods
Study population
We conducted a case–control study of 850 individuals.
Four hundred and fifty patients diagnosed with CRC
at CHA Bundang Medical Center (Seongnam, South
Korea) were enrolled from June 2004 to January 2009.
This study only included CRC patients who had under-
gone surgical resection with a curative intent and who
had histologically confirmed adenocarcinoma. Within
the CRC cohort, 264 consecutive patients with colon
cancer and 186 consecutive patients with rectal cancer
underwent primary surgery. Tumor staging of CRCs was
performed according to the sixth edition of the Ameri-
can Joint Committee on Cancer (AJCC) staging manual.
The control group consisted of 400 individuals randomly
selected following a health screening. This screening ex-
cluded patients with a history of cancer. Individuals
were diagnosed with MetS if they possessed three or
more of the following five risk factors: body mass index
(BMI) ≥25.0 kg/m2; triglycerides (TG) ≥150 mg/dL;
high density lipoprotein-cholesterol (HDL-C) <40 mg/
dL for men or <50 mg/dL for women; BP ≥130/
85 mmHg or currently taking anti-hypertension medi-
cation; and fasting blood sugar (FBS) ≥100 mg/dL or
currently taking hypoglycemic medication. All study
subjects were ethnic Koreans and provided written
informed consent. The study protocol was approved
by the Institutional Review Board of CHA Bundang
Medical Center, Seongnam, South Korea.
Phenotype measurements
Anthropometric measurements included BMI. Systolic
and diastolic BP of subjects were measured in the seated
position after 10 min of rest. For measurements of
physiological parameters, 3 ml blood was obtained after
fasting overnight. The hexokinase method was employed
to measure FBS levels; samples were analyzed in dupli-
cate by an automated analyzer (TBA 200FR NEO,
Toshiba Medical Systems, Tokyo, Japan). TG and HDL-
C levels were determined by enzymatic colorimetric
methods using commercial reagent sets (TBA 200FR
NEO, Toshiba Medical Systems).
Genotyping
DNA was extracted from leukocytes using a G-DEX™ II
Genomic DNA Extraction kit (Intron Biotechnology,
Seongnam, Korea) according to the manufacturer’s in-
structions. VEGF genotypes were analyzed by TaqMan
allelic discrimination analysis. Genotyping of the VEGF
1451C > T, VEGF 1612G > A, and VEGF 1725G > A
polymorphisms was determined using real-time poly-
merase chain reaction (PCR) (RG-6000, Corbett Research,
Australia) for allelic discrimination. Primers and TaqMan
probes were designed using Primer Express Software
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systems (Foster City, CA, USA). The reporter dyes used
were FAM and JOE. The primer sequences for amplifica-
tion are as follows: VEGF 1451C > T: forward 5′- ACG
GAC AGA AAG ACA GAT CAC AG -3′ and reverse 5′-
CCC AAA GCA CAG CAA TGT C -3′. The selected
probes were 5′-FAM- TGA GGA CAC CGG CTC TGA
CC -TAMRA-3′ (C allele detecting probe) and 5′-JOE-
TGA GGA CAC TGG CTC TGA CC -TAMRA-3′ (T al-
lele detecting probe). VEGF 1612G >A: forward 5′- TTC
GCT TAC TCT CAC CTG CTT C -3′ and reverse
5′- GCT GTC ATG GGC TGC TTC T -3′. The selected
probes were 5′-FAM- CCC AGG AGG CCA CTG GCA
-TAMRA-3′ (G allele detecting probe) and 5′-JOE- CCC
AGG AGA CCA CTG GCA -TAMRA-3′ (A allele detect-
ing probe). VEGF 1725G >A: forward 5′- CAT GAC
AGC TCC CCT TCC T -3′ and reverse 5′- TGG TTT
CAATGG TGT GAG GAC -3′. The selected probes were
5′-FAM- CTT CCT GGG GTG CAG CCT AA -TAMRA-
3′ (G allele detecting probe) and 5′-JOE- CTT CCT GGG
ATG CAG CCT AA -TAMRA-3′ (A allele detecting
probe). For each polymorphism, 30% of the PCR assays
were randomly selected and repeated, followed by DNA se-
quencing, to validate the experimental findings. Sequencing
was performed using an ABI 3730xl DNA Analyzer
(Applied Biosystems, Foster City, CA, USA). The con-
cordance of the quality control samples was 100%.
Quantitative real-time PCR
To perform quantitative real-time PCR (qRT-PCR), total
RNA was extracted from 47 tumor and tumor-adjacent
tissues from 47 CRC patients by using TRIzol Reagent
(Invitrogen, Grand Island, NY, USA) according to the
manufacturer’s instructions. cDNA was made from total
RNA with the SuperScript III First-Strand Synthesis
System (Invitrogen, Grand Island, NY, USA). Measure-
ment of the VEGF mRNA was determined using real-
time PCR (RG-6000, Corbett Research, Australia). The
expression level of VEGF mRNA in 47 tumor and
tumor-adjacent tissues was compared by a comparative
CT (2
-ΔΔC
T) method with housekeeping internal control,
18 s rRNA. The primer sequences for amplification are
as follows: 18 s rRNA: forward 5′- AAC TTT CGA
TGG TAG TCG CCG -3′ and reverse 5′- CCT TGG
ATG TGG TAG CCG TTT -3′. VEGF: forward 5′- TGA
GCT TCC TAC AGC ACA AC -3′ and reverse 5′- ATT
TAC ACG TCT GCG GAT CTT -3′.
Statistical analysis
To analyze baseline characteristics, odds ratios (ORs)
and 95% confidence intervals (95% CIs) from univariate
logistic regression were used to compare patient and con-
trol baseline data. Genetic associations of VEGF 1451C >
T, 1612G >A, and 1725G >A polymorphisms with MetSand CRC susceptibility were calculated using adjusted
odds ratios (AORs) and 95% CIs from multivariate logistic
regression. The variables age, gender, and MetS risk fac-
tors were selected as adjustment variables. To estimate
MetS and CRC risk, we used three genetic susceptibility
models: additive, dominant, and recessive. All VEGF 3′-
UTR genotypes were converted into numeric values for
logistic regression according to their genotypes. Wild ho-
mozygotes were assigned “0” in all models. Heterozygotes
were assigned “1” in additive and dominant models and
“0” in the recessive model. Mutant homozygotes were
assigned “1” in dominant and recessive models and “2”
in the additive model. Gene-environment interaction
analysis was performed using the open-source multifactor
dimensionality reduction (MDR) software package (v.2.0)
available from www.epistasis.org. The comparisons of
relative VEGF mRNA expression were analyzed by Mann–
Whitney, Krusukal-Wallis, and Wilcoxon signed rank tests.
Analyses were performed using GraphPad Prism 4.0
(GraphPad Software Inc., San Diego, CA, USA) and
Medcalc version 12.7.1.0 (Medcalc Software, Mariakerke,
Belgium). Haplotypes for multiple loci were estimated using
the expectation-maximization algorithm with SNPAlyze
(Version 5.1; DYNACOM Co, Ltd, Yokohama, Japan).
Results
In this study, we collected data for 450 CRC patients
(264 colon cancer [CC] and 186 rectal cancer [RC] pa-
tients), including 212 men and 238 women. Both CC
and RC groups have higher portion of tumor size ≥5 cm
and tumor node metastasis (TNM) stage II/III (Table 1).
The presence of MetS was associated with CRC suscep-
tibility (CC group: OR = 1.90; 95% CI = 1.35 - 2.66;
p < .001; RC group: OR = 2.07; 95% CI = 1.43 - 3.01;
p < .001). Of MetS risk factors, lower HDL-C (<40 mg/
dL for men or <50 mg/dL for women) strongly contrib-
uted to CC and RC risk (CC group: OR = 3.09; 95%
CI = 2.18 - 4.37; p < .001; RC group: OR = 3.40; 95% CI =
2.32 - 4.97; p < .001). Table 2 shows the distributions of
genotypes and haplotypes for VEGF 1451C > T, 1612G >
A, and 1725G >A polymorphisms stratified by the pres-
ence of MetS. The VEGF 3′-UTR genotype frequencies of
controls were consistent with the Hardy-Weinberg equi-
librium. Table 3 presents AOR values for MetS, CC, and
RC risk by VEGF 3′-UTR polymorphisms. VEGF 1451C >
T was significantly associated with RC risk (Dominant
model: AOR = 1.58; 95% CI = 1.09 - 2.28; p = 0.015)
whereas VEGF 1725G >A correlated with MetS risk
(Dominant model: AOR = 1.61; 95% CI = 1.06 - 2.46; p =
0.026). As a similar pattern, in haplotype analysis, VEGF
1451T/1612G/1725G contributed to RC risk (AOR = 1.40;
95% CI = 1.03 - 1.92; p = 0.030) while VEGF 1451C/
1612A/1725A was involved with MetS risk (AOR = 1.54;
95% CI = 1.02 - 2.34; p = 0.041).
Table 1 Baseline characteristics in colorectal cancer patients and control subjects
Characteristics Control CC OR (95% CI) p RC OR (95% CI) p
N 400 264 186
Age (mean±SD) 60.89 ± 11.72 61.85 ± 12.85 1.01 (0.99 - 1.02) 0.320 62.33 ± 11.46 1.01 (1.00 - 1.03) 0.165
Gender (male), n (%) 170 (42.5) 124 (47.0) 1.20 (0.88 - 1.64) 0.257 88 (47.3) 1.21 (0.86 - 1.72) 0.275
Metabolic syndrome, n (%) 95 (23.8) 98 (37.1) 1.90 (1.35 - 2.66) <.001 73 (39.2) 2.07 (1.43 - 3.01) <.001
Anti-HTN drug or BP≥ 130/85 mmHg, n (%) 157 (39.3) 159 (60.2) 2.34 (1.71 - 3.22) <.001 120 (64.5) 2.81 (1.96 - 4.04) <.001
Anti-DM drug or FBS≥ 100 mg/dl, n (%) 166 (41.5) 149 (56.4) 1.83 (1.33 - 2.50) <.001 104 (55.9) 1.79 (1.26 - 2.54) 0.001
TG≥ 150 mg/dl, n (%) 135 (33.8) 67 (25.4) 0.67 (0.47 - 0.94) 0.022 46 (24.7) 0.65 (0.44 - 0.95) 0.029
BMI≥ 25 kg/m2, n (%) 93 (23.3) 65 (24.6) 1.08 (0.75 - 1.55) 0.685 51 (27.4) 1.25 (0.84 - 1.85) 0.276
HDL-C < 40(male)/50(female) mg/dl, n (%) 78 (19.5) 113 (42.8) 3.09 (2.18 - 4.37) <.001 84 (45.2) 3.40 (2.32 - 4.97) <.001
Tumor size
<5 cm - 94 (35.6) - - 87 (46.8) - -
≥5 cm - 170 (64.4) - - 99 (53.2) - -
TNM stage, n (%)
I - 22 (8.3) - - 20 (10.8) - -
II - 118 (44.7) - - 71 (38.2) - -
III - 94 (35.6) - - 79 (42.5) - -
IV - 30 (11.4) - - 16 (8.6) - -
Colon cancer (CC), Rectal cancer (RC), Odds ratio (OR), Confidence interval (CI), Standard deviation (SD), Blood pressure (BP), Fasting blood sugar (FBS),
Hypertension (HTN), Diabetes mellitus (DM), Triglycerides (TG), Body mass index (BMI), High density lipoprotein-cholesterol (HDL-C), Tumor node metastasis (TNM).
ORs and p values were calculated by univariate logistic regression.
Table 2 Genotype and haplotype frequencies of VEGF 3′-UTR polymorphisms
Without MetS With MetS
Genotype/Haplotype Control (n = 305) CC (n = 166) RC (n = 113) Control (n = 95) CC (n = 98) RC (n = 73)
VEGF 1451CC 209 (68.5) 108 (65.1) 64 (56.6) 65 (68.4) 72 (73.5) 45 (61.6)
VEGF 1451CT 81 (26.6) 50 (30.1) 43 (38.1) 29 (30.5) 23 (23.5) 27 (37.0)
VEGF 1451TT 15 (4.9) 8 (4.8) 6 (5.3) 1 (1.1) 3 (3.1) 1 (1.4)
HWE-p 0.059 0.483 0.724 0.251 0.493 0.167
VEGF 1612GG 213 (69.8) 127 (76.5) 87 (77.0) 67 (70.5) 68 (69.4) 54 (74.0)
VEGF 1612GA 83 (27.2) 36 (21.7) 21 (18.6) 27 (28.4) 29 (29.6) 18 (24.7)
VEGF 1612AA 9 (3.0) 3 (1.8) 5 (4.4) 1 (1.1) 1 (1.0) 1 (1.4)
HWE-p 0.791 0.809 0.022 0.336 0.271 0.714
VEGF 1725GG 278 (91.1) 147 (88.6) 96 (85.0) 81 (85.3) 79 (80.6) 61 (83.6)
VEGF 1725GA 27 (8.9) 19 (11.4) 17 (15.0) 14 (14.7) 19 (19.4) 12 (16.4)
VEGF 1725AA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
HWE-p 0.419 0.434 0.387 0.438 0.288 0.444
VEGF 1451C/1612G/1725G 398 (65.2) 221 (65.6) 140 (61.9) 130 (68.4) 134 (68.4) 96 (65.8)
VEGF 1451T/1612G/1725G 111 (18.2) 66 (19.9) 55 (24.3) 31 (16.3) 29 (14.8) 29 (19.9)
VEGF 1451C/1612A/1725G 74 (12.1) 26 (7.8) 14 (6.2) 15 (7.9) 14 (7.1) 9 (6.2)
VEGF 1451C/1612A/1725A 27 (4.4) 16 (4.8) 17 (7.5) 14 (7.4) 17 (8.7) 11 (7.5)
VEGF 1451C/1612G/1725A 0 (0.0) 3 (0.9) 0 (0.0) 0 (0.0) 2 (1.0) 1 (0.7)
Vascular endothelial growth factor (VEGF), Colon cancer (CC), Rectal cancer (RC), Metabolic syndrome (MetS), Hardy-Weinberg equilibrium (HWE).
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Table 3 Adjusted odds ratios for metabolic syndrome, colon cancer, and rectal cancer risks according to VEGF 3′-UTR
variants
MetS risk CC risk RC risk
Genotype/Haplotype Model Wild type AOR (95% CI)* p AOR (95% CI)** p AOR (95% CI)** p
VEGF 1451C > T Additive CC 0.80 (0.61 - 1.05) 0.105 1.05 (0.79 - 1.39) 0.742 1.40 (1.03 - 1.91) 0.031
Dominant CC 0.85 (0.62 - 1.16) 0.295 1.04 (0.74 - 1.46) 0.813 1.58 (1.09 - 2.28) 0.015
Recessive CC 0.36 (0.14 - 0.96) 0.041 1.16 (0.53 - 2.57) 0.709 1.12 (0.45 - 2.80) 0.804
VEGF 1612G > A Additive GG 1.02 (0.76 - 1.36) 0.920 0.82 (0.59 - 1.12) 0.216 0.83 (0.58 - 1.18) 0.304
Dominant GG 1.11 (0.80 - 1.54) 0.521 0.81 (0.57 - 1.15) 0.239 0.74 (0.50 - 1.11) 0.149
Recessive GG 0.38 (0.11 - 1.33) 0.130 0.68 (0.21 - 2.21) 0.521 1.48 (0.52 - 4.19) 0.458
VEGF 1725G > A Additive GG 1.61 (1.06 - 2.46) 0.026 1.34 (0.83 - 2.16) 0.235 1.51 (0.90 - 2.55) 0.118
Dominant GG 1.61 (1.06 - 2.46) 0.026 1.34 (0.83 - 2.16) 0.235 1.51 (0.90 - 2.55) 0.118
Recessive GG - - - - - -
VEGF 1451C/1612G/1725G Others 1.14 (0.92 - 1.43) 0.232 1.04 (0.82 - 1.31) 0.762 0.87 (0.67 - 1.12) 0.279
VEGF 1451T/1612G/1725G Others 0.80 (0.61 - 1.05) 0.101 1.05 (0.79 - 1.41) 0.735 1.40 (1.03 - 1.92) 0.030
VEGF 1451C/1612A/1725G Others 0.73 (0.50 - 1.07) 0.111 0.69 (0.47 - 1.02) 0.066 0.56 (0.34 - 0.90) 0.017
VEGF 1451C/1612A/1725A Others 1.54 (1.02 - 2.34) 0.041 1.12 (0.69 - 1.80) 0.652 1.42 (0.86 - 2.36) 0.170
Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF).
*AORs and p values were adjusted by age and gender. **AORs and p values were adjusted by age, gender, and MetS risk factors.
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play of genetic and environmental factors, we calculated
gene-environment combined effects between MetS and
VEGF 3′-UTR polymorphisms. Preferentially, we sought
to determine whether the contribution of VEGF 3′-UTR
genetic variants to CRC susceptibility varied with the
presence of MetS (Table 4). The significant involvements
of VEGF 1451C > T (Dominant model: AOR = 1.67; 95%
CI = 1.07 - 2.61; p = 0.023) and VEGF 1451T/1612G/
1725G (AOR = 1.45; 95% CI = 1.00 - 2.09; p = 0.047)
with RC risk were found in the absence of MetS. Table 5
displays gene-environment interaction effects between
VEGF 3′-UTR polymorphisms and MetS. We examined
all possible combinations of gene-environment interac-
tions using MDR methods. The combination of VEGF
1451C > T and MetS was the best model to evaluate RC
risk (Cross validation consistency = 9/10), while the com-
bination of VEGF 1725G >A and MetS was the most
appropriate model to assess CC risk (Cross validation
consistency = 7/10). The interaction of VEGF 1451C > T
and MetS contributed to increased RC risk (AOR = 3.15;
95% CI = 1.74 - 5.70; p < .001) whereas the combination
of VEGF 1725G >A and MetS was involved with elevated
CC risk (AOR = 2.68; 95% CI =1.30 - 1.55; p = 0.008).
Finally, we quantified expression of VEGF in tissue
samples and looked for differences in expression based
on the tested haplotypes and genotypes. VEGF expres-
sion as a function of each VEGF 3′-UTR genotype or
haplotype is presented in Table 6. Relative VEGF mRNA
levels in samples with the 1451T/1612G/1725G were
significantly decreased relative to the 1451C/1612G/
1725G (p < .05). In contrast, relative VEGF mRNA levelsin samples with the 1451C/1612A/1725A were signifi-
cantly increased from levels in samples with the 1451C/
1612G/1725G (p < .05). Table 7 shows VEGF expression
between tumor and tumor-adjacent tissues according to
studied polymorphisms. Relative VEGF mRNA expres-
sion of tumor-tissues is significantly increased in each
wild genotype while not in each variant genotype.
(Additional file 1: Table S1) displays the frequencies of
MetS and VEGF 3′-UTR genotypes according to clini-
copathological features of CRC. The frequency of
VEGF 1451C > T was different between the CC and
RC groups, but this difference was not statistically sig-
nificant (p = 0.081).
Discussion
In the present study, we investigated whether VEGF
1451C > T, 1612G > A, and 1725G > A are involved with
CRC susceptibility. We identified that VEGF 1451C > T
was significantly associated with RC risk whereas VEGF
1725G > A correlated with MetS risk. Of the gene-
environment combined effects, the interaction of VEGF
1451C > T and MetS contributed to increased RC risk
whereas the combination of VEGF 1725G > A and MetS
was involved with elevated CC risk. Furthermore, quan-
titative real-time PCR analysis revealed that relative
VEGF mRNA expression in tumor tissues varied with
VEGF 1451T/1612G/1725G and 1451C/1612A/1725A
haplotypes. To our knowledge, VEGF 1451C > T and
1725G > A may play roles in CRC susceptibility.
Polymorphisms within the VEGF gene are a current
topic of interest within the cancer epidemiology field.
There are several association studies showing that
Table 4 Stratified effects of metabolic syndrome on colon cancer and rectal cancer risks by VEGF 3′-UTR variants
CC risk RC risk
Genotype/Haplotype Model Subgroup Wild type AOR (95% CI) p AOR (95% CI) p
VEGF 1451C > T Additive Without MetS CC 1.12 (0.80 - 1.54) 0.513 1.42 (0.99 - 2.03) 0.055
With MetS CC 0.89 (0.50 - 1.59) 0.701 1.44 (0.77 - 2.67) 0.255
Dominant Without MetS CC 1.18 (0.79 - 1.77) 0.416 1.67 (1.07 - 2.61) 0.023
With MetS CC 0.78 (0.41 - 1.49) 0.456 1.44 (0.74 - 2.78) 0.280
Recessive Without MetS CC 0.99 (0.41 - 2.40) 0.985 1.09 (0.41 - 2.87) 0.868
With MetS CC 3.07 (0.30 - 31.00) 0.342 2.14 (0.13 - 35.71) 0.595
VEGF 1612G > A Additive Without MetS GG 0.73 (0.49 - 1.07) 0.105 0.81 (0.53 - 1.24) 0.328
With MetS GG 1.10 (0.61 - 2.02) 0.746 0.97 (0.50 - 1.87) 0.928
Dominant Without MetS GG 0.71 (0.46 - 1.09) 0.117 0.69 (0.42 - 1.14) 0.148
With MetS GG 1.13 (0.60 - 2.14) 0.704 0.93 (0.46 - 1.89) 0.850
Recessive Without MetS GG 0.58 (0.15 - 2.17) 0.416 1.51 (0.49 - 4.61) 0.469
With MetS GG 0.78 (0.05 - 13.40) 0.867 1.72 (0.10 - 28.53) 0.705
VEGF 1725G > A Additive Without MetS GG 1.34 (0.72 - 2.49) 0.360 1.82 (0.95 - 3.48) 0.072
With MetS GG 1.37 (0.62 - 2.98) 0.435 1.20 (0.51 - 2.85) 0.672
Dominant Without MetS GG 1.34 (0.72 - 2.49) 0.360 1.82 (0.95 - 3.48) 0.072
With MetS GG 1.37 (0.62 - 2.98) 0.435 1.20 (0.51 - 2.85) 0.672
Recessive Without MetS GG - - - -
With MetS GG - - - -
VEGF 1451C/1612G/1725G Without MetS Others 1.06 (0.80 - 1.40) 0.697 0.87 (0.63 - 1.19) 0.375
With MetS Others 0.95 (0.61 - 1.49) 0.840 0.80 (0.50 - 1.28) 0.354
VEGF 1451T/1612G/1725G Without MetS Others 1.13 (0.80 - 1.58) 0.495 1.45 (1.00 - 2.09) 0.047
With MetS Others 0.90 (0.51 - 1.58) 0.705 1.36 (0.77 - 2.42) 0.292
VEGF 1451C/1612A/1725G Without MetS Others 0.61 (0.38 - 0.97) 0.038 0.48 (0.26 - 0.86) 0.015
With MetS Others 1.04 (0.48 - 2.25) 0.930 0.87 (0.37 - 2.08) 0.760
VEGF 1451C/1612A/1725A Without MetS Others 1.09 (0.58 - 2.05) 0.795 1.75 (0.93 - 3.28) 0.081
With MetS Others 1.13 (0.53 - 2.43) 0.745 1.08 (0.47 - 2.51) 0.854
Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF).
AORs and p values were adjusted by age and gender.
Table 5 Combined effects of metabolic syndrome and VEGF 3′-UTR variants on colon cancer and rectal cancer risks
CC risk RC risk
Without MetS With MetS Without MetS With MetS
Genotype AOR (95% CI) p AOR (95% CI) p AOR (95% CI) p AOR (95% CI) p
VEGF 1451CC 1.00 (reference) 2.17 (1.43 - 3.28) <.001 1.00 (reference) 2.22 (1.38 - 3.57) 0.001
VEGF 1451CT+TT 1.18 (0.79 - 1.77) 0.416 1.76 (0.98 - 3.16) 0.060 1.67 (1.07 - 2.61) 0.023 3.15 (1.74 - 5.70) <.001
VEGF 1612GG 1.00 (reference) 1.68 (1.12 - 2.53) 0.013 1.00 (reference) 1.94 (1.24 - 3.01) 0.003
VEGF 1612GA+AA 0.71 (0.46 - 1.09) 0.117 1.81 (1.03 - 3.19) 0.040 0.69 (0.42 - 1.14) 0.148 1.66 (0.88 - 3.15) 0.117
VEGF 1725GG 1.00 (reference) 1.88 (1.29 - 2.73) 0.001 1.00 (reference) 2.17 (1.44 - 3.27) <.001
VEGF 1725GA+AA 1.34 (0.72 - 2.49) 0.360 2.68 (1.30 - 5.55) 0.008 1.82 (0.95 - 3.48) 0.072 2.49 (1.11 - 5.57) 0.027
Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF).
AORs and p values were adjusted by age and gender.
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Table 6 VEGF mRNA expression levels (mean ± SE) according to VEGF 3′-UTR genotypes and haplotypes
Tumor-adjacent (n = 47) p Tumor (n = 47) p
VEGF 1451CC (n = 32) 1.00 ± 0.45 0.445 1.00 ± 0.47 0.158
VEGF 1451CT+TT (n = 15) 2.54 ± 2.13 0.02 ± 0.01
VEGF 1612GG (n = 33) 1.00 ± 0.54 0.008 1.00 ± 0.67 0.156
VEGF 1612GA+AA (n = 14) 6.76 ± 4.24 3.67 ± 2.38
VEGF 1725GG (n = 41) 1.00 ± 0.40 0.038 1.00 ± 0.58 0.011
VEGF 1725GA+AA (n = 6) 5.98 ± 4.30 7.61 ± 5.43
VEGF 1451C/1612G/1725G (n = 61) 1.00 ± 0.35 0.064 1.00 ± 0.39 0.027
VEGF 1451T/1612G/1725G (n = 18) 2.61 ± 2.19 0.02 ± 0.01
VEGF 1451C/1612A/1725G (n = 9) 2.72 ± 1.52 0.44 ± 0.42
VEGF 1451C/1612A/1725A (n = 5) 7.92 ± 6.08 4.59 ± 3.28
Standard error (SE), Vascular endothelial growth factor (VEGF). p values were calculated by Mann–Whitney and Kruskal-Wallis tests.
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http://www.biomedcentral.com/1471-2407/14/881VEGF −2578C >A, −1498T >C (−460T >C), −1154G >
A, −634G >C (405G >C), and 936C >T correlate with
CRC risk [6], and the following alleles: VEGF −2578A,
−1498T, −1154A, −634C, and 936T: are associated with re-
duced VEGF expression [25-27]. Increased CRC incidence
seems to occur in genotypes that cause both low (VEGF
−2578A and 936T) and high (VEGF −1498C and −634G)
VEGF expression [24,28,29].
Angiogenesis under physiological conditions is a strictly
regulated process on many levels, including spatial and
temporal expression of genes, as well as intensity of the
cellular response. Indeed, in the adult body, angiogenesis
is constantly suppressed; the levels of anti-angiogenic mol-
ecules predominate in every tissue. However, failure of the
regulatory processes that inhibit angiogenesis leads to the
excessive generation of blood vessels that participate in
cancer progression [30]. Higher VEGF expression can
increase tumor-related angiogenesis and metastasis [31].
The role of angiogenesis as a prognostic factor of carcino-
genesis and cancer progression, however, is still controver-
sial [32,33]. Weidner et al. [3] first reported a directTable 7 VEGF mRNA expression (mean ± SE) between tumor a
genotypes and haplotypes
Tumor-adjacent (n
VEGF 1451CC (n = 32) 1.00 ± 0.45
VEGF 1451CT+TT (n = 15) 1.00 ± 0.84
VEGF 1612GG (n = 33) 1.00 ± 0.54
VEGF 1612GA+AA (n = 14) 1.00 ± 0.63
VEGF 1725GG (n = 41) 1.00 ± 0.40
VEGF 1725GA+AA (n = 6) 1.00 ± 0.72
VEGF 1451C/1612G/1725G (n = 61) 1.00 ± 0.35
VEGF 1451T/1612G/1725G (n = 18) 1.00 ± 0.81
VEGF 1451C/1612A/1725G (n = 9) 1.00 ± 0.56
VEGF 1451C/1612A/1725A (n = 5) 1.00 ± 0.77
Standard error (SE), Vascular endothelial growth factor (VEGF). p values were calculacorrelation between the incidence of metastasis and the
number and density of blood vessels in invasive breast car-
cinomas. Similar studies have made this association in
gastrointestinal [34] and colorectal cancers [32,35-39]. An
association between elevated angiogenesis and both a high
prevalence of metastases and a subsequent decrease in
survival has been reported for a vast majority of solid tu-
mors [32,35-39]. Several studies have revealed high angio-
genic activity in CRC, which was more likely correlated
with aggressive histological and pathological characteris-
tics including parietal invasion, tumor stage, grade of
tumor differentiation, metastatic rates, and poor survival
rates [32,40,41]. Also, Gurzu et al. [32] reported that aug-
mented levels angiogenesis in CRC were higher during
early stages of tumor proliferation, but did not progres-
sively increase as the tumors advanced. For these reasons,
anti-angiogenesis is one possible target for cancer preven-
tion and therapy.
However, anti-angiogenesis can induce the metastatic
potential of cancer. Inhibition of VEGF/VEGF receptor
(VEGFR) signaling causes a decrease in nutrient andnd tumor-adjacent tissues according to VEGF 3′-UTR
= 47) Tumor (n = 47) p
75.37 ± 35.42 0.029
0.59 ± 0.30 0.125
52.24 ± 35.00 0.001
28.36 ± 18.39 0.143
30.65 ± 17.78 0.011
39.00 ± 27.83 0.203
67.56 ± 26.35 <.001
0.50 ± 0.25 0.133
10.93 ± 10.43 0.481
39.15 ± 27.98 0.210
ted by Wilcoxon signed rank test.
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http://www.biomedcentral.com/1471-2407/14/881oxygen levels, inducing hypoxia [42]. One of the crucial
steps in the cellular response to hypoxia is the stabilization
of hypoxia-inducible factor (HIF)-1 in low-oxygen condi-
tions. As a consequence, genes directly regulated by this
transcription factor are activated. Because HIF-1 modu-
lates the transcription of genes involved in glycolytic me-
tabolism, oxygen consumption, survival, angiogenesis,
migration, and invasion, its stabilization has a dramatic
impact on the gene expression profile and ultimately on
the behavior of the cells [43]. For example, cancer cells
react to the hypoxia caused by anti-angiogenic signals by
reprogramming their metabolism, thus increasing the
uptake of glucose to sustain energy production through
glycolysis. This phenomena is referred to as the Warburg
effect [43]. Also, the epithelial-mesenchymal transition
when stabilized HIF-1 transactivates the Met proto-
oncogene, the receptor for hepatocyte growth factor [44].
In addition, recent data suggest that VEGF supplementa-
tion may inhibit invasion and epithelial-mesenchymal
transition of cancer cells [45]. Therefore, for cancer
prevention and therapy, it may be important to keep
VEGF expression levels within a normal range. Previ-
ous reports showed that polymorphic events affecting
the mRNA expression of VEGF and VEGFR genes
could contribute to the survival duration of cancer
patients receiving anti-angiogenic treatment [46-49].
The VEGF −2578A/−1498C/−634G haplotype showed
a shorter survival time in multiple myeloma patients
treated with thalidomide [46]. The progression-free
survival duration of metastatic renal cell carcinoma
patients who received bevacizumab treatment varied be-
tween VEGFR1 rs7993418 alleles [47]. VEGF −2578CC,
−1498TT, and −634CC were associated with a poorer
prognosis and progression-free survival duration in
advanced renal cell carcinoma patients receiving first-
line sunitinib [48]. VEGF −634CC displayed relatively
shorter progression free survival duration in advanced
castration-resistant prostate cancer patients treated with
metronomic cyclophosphamide [49].
We identified an association between lower mRNA ex-
pression and RC risk in the VEGF 1451T carrier. More-
over, VEGF 1451T carrier combined with MetS was
linked to increased RC risk, whereas the combination of
higher mRNA expression in the VEGF 1725A carrier
and MetS was linked to elevated CC risk. VEGF 1451T
carrier could directly contribute to RC risk, but the
VEGF 1725A allele could not have influence on CC risk
alone. In other studies, weakened VEGF/VEGFR signal-
ing was shown to cause a decrease in oxygen levels, and
the HIF-1 transcription factor is stabilized in insulin re-
sistance conditions [42,50]. We hypothesize that low
oxygen conditions in VEGF 1451T carrier and HIF-1 ac-
tivation in MetS patients may lead to early cancer devel-
opment. Activated HIF-1 drives the transcription of over60 genes that are involved in cancer biology, including
angiogenesis, cell survival, and glucose metabolism [51].
VEGF 1725A carrier may influence a pathological angio-
genesis step after persistent HIF-1 activation.
Genetic variation in the 3′-UTR region could affect the
stability and translation of the mRNA through altered
miRNA binding affinity. Currently, there are no data to
directly show altered miRNA binding activity depending
on VEGF 3′-UTR polymorphisms. Further studies are
needed to directly test for miRNA binding activity to
VEGF 3′-UTR polymorphisms to determine the mechan-
ism by which these polymorphisms may influence cellular
proliferation and cancer progression. These studies may
have great clinical impact for all diseases related to abnor-
mal angiogenesis and hypoxic conditions.
There are several limitations in this study. First, the
mechanism by which 1451C > T, 1612G > A, and
1725G > A polymorphisms in the VEGF gene affect de-
velopment of CRC is still unclear. Further studies of whole
VEGF sequence variants and their biological functions
would uncover the role of these VEGF polymorphisms
and haplotypes in the development and progression of
CRC. Second, the present study lacked information
regarding additional environmental risk factors (smoking,
alcohol intake, caffeine intake, red meat intake, and multi-
vitamin use) and clinical characteristics (survival time, re-
lapse, death, chemotherapy, and radiotherapy) in the CRC
patient cohort. These factors may contribute to overall
CRC risk. Lastly, the population of this study was re-
stricted to patients of Korean ethnicity. Because frequen-
cies of genetic polymorphisms often vary between ethnic
groups, more studies in diverse ethnic populations are
warranted to clarify the association between VEGF 3′-
UTR polymorphisms and CRC.
Conclusion
We investigated the involvement of VEGF polymor-
phisms 1451C > T, 1612G > A, and 1725G > A with CRC
susceptibility in the present study. VEGF 1451C > T and
1725G > A could contribute to CRC susceptibility when
combined with the presence of MetS. Moreover, VEGF
mRNA expression varied in tumor tissues depending on
the combination of 3′-UTR polymorphic alleles present.
Although results from our study provide the first evi-
dence for VEGF 1451C > T, 1612G > A, and 1725G > A
as potential biomarkers for CRC prevention, a prospect-
ive study on a larger cohort of patients is warranted to
validate these findings.Additional file
Additional file 1: Table S1. The frequencies of MetS and VEGF 3′-UTR
genotypes according to clinicopathological features of CRC.
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